Introduction

Our vision is to create affordable and accessible treatment, and a happy, healthy New Zealand.

Eqalis was established in early 2019, with the aim of helping to build an industry from the ground up from the horticultural heart of the Bay of Plenty.

Since the earliest days of this emerging category, we’ve believed in the importance of a team and culture based on transparency, tenacity, agility, and innovation. And that belief drove us to where we are today. At the very forefront of New Zealand medical marijuana.

Driven by science

We’re leading the way with research.

As our industry continues to grow, a laser-focus on research, supply and innovation will only become more important.

The Eqalis Story

The body requires balance.

Based on medicinal cannabis’s ability to bring the body back into its natural balance, the name ‘Eqalis’ comes from two key principles.

Equilibrium
Cannabis has a powerful ability to bring the body back to its natural state of equilibrium. Using the plant’s numerous beneficial elements, we’ve produced medical marijuana that works throughout the entire body. All with the ultimate goal of homeostasis; the total stability of the body’s internal systems.

Quality Adjusted Life Year (QALY)
QALY, a globally-recognised system that determines a medicine’s value based on the quality of life it provides. QALY is central to what we do – growing our finest quality ingredients under the strictest of conditions, so we can help build a healthier and happier New Zealand.

Representing the Eqalis brand is the Statera icon. It symbolises balance, wholeness, symmetry, targeted relief, and continuous development, with the suggestion of a flower alluding to our horticultural heritage.

We are currently collaborating with world-class growers, industry experts and stakeholders on both a national and global scale to bring only the best medical solutions. In late 2022, we expect to be launching our New Zealand grown and manufactured CBD-based medicine.

Our team

We have merged with Cannasouth

On 1 June 2023 Eqalis merged with leading medicinal cannabis company Cannasouth.

For more information about the merger, click here

For more information on our Governance and Leadership teams, click here

Our Clinical Advisor Board

The Clinical Advisory Board was formed in order to seek advice from key clinicians and ensure decisions they make are focused on medical professional requirements and patient focused care. This committee is comprised of senior figures across a range of medical backgrounds.

MBChB (Otago), DA (London) FANZCA

Dr Wardill graduated from Otago Medical School in 1985, and following his house surgeon training in Auckland, carried out a short stint as a GP in Auckland during 1988-1989. He then went to London from 1989 to 1992 and started in anaesthesia at Greenwich in the UK. He returned to New Zealand late in 1992 as an Anaesthetist Registrar at Waikato Hospital, Auckland Hospital, Starship & Middlemore Hospital. He came to Tauranga as a Fellow in 1999 having completed his fellowship at the Royal Prince Alfred Hospital in Sydney. He was a consultant anaesthetist at Tauranga Hospital from 2000 to 2017, and is now full time at Grace Hospital a private hospital in Tauranga. He is mostly involved in Orthopaedics & Urology and has developed an interest in the potential of medical cannabis.

RegPharmNZ, MPS, DIP, Pharm (CIT)

Mr Gregory has been a community Pharmacist for 30 years. He is married to Helen (also a Pharmacist) and they have three children. Together they have owned Unichem Brookfield Pharmacy since the mid 90’s. Mr Gregory has been a member of many boards during this time including but not limited to Waipuna Hospice, BOP Asthma and Respiratory, and BOP Community Pharmacy Group. Outside of Pharmacy Mr Gregory has a passion for aviation and enjoyed flying for many years as a private pilot.

RegPharmNZ, FPS, MRPharmS, MHSc (Distn), PGDipClinPharm (Distn)

Elizabeth Plant is Chief Medical Officer of EQALIS Research Ltd, a new medical cannabis company, currently conducting research with the aim of developing medical cannabis products for New Zealand. Prior to this she has held a number of senior pharmacy roles including independent consulting and Chief Pharmacist of Taranaki DHB for nearly 20 years. She was the President of the NZ Pharmaceutical Society for 5 years (2008-2013) and a ministerial appointment to the NHITB (National Health IT Board) for 8 years (2008-2016). She was a founding and active member of all the New Zealand medication safety committees over the past 20 years and a member of the original PHARMAC Hospital Procurement Advisory Committee (HPAC) serving for 3 years.
She has been a consultant specialising in development of medication optimisation frameworks, medication safety, medication management, electronic medication management, quality improvement and audit, clinical change management, leadership and workforce development, cultural organisational change and strategic development. She has operated at the highest level in developing national government policy as well as at operational, clinical, technical and governance level. She is a registered pharmacist with fellowships awarded from the Pharmaceutical Society and College of Pharmacists. She has an Advanced Clinical Pharmacy Post Graduate Diploma and a Masters in Health Sciences, both with distinction. She is a trained Quality Health Auditor and very experienced in implementing electronic medication systems with the associated clinical change management.

keyboard_arrow_up